» Articles » PMID: 22447467

Low Dose of Hydrochlorothiazide, in Combination with Angiotensin Receptor Blocker, Reduces Blood Pressure Effectively Without Adverse Effect on Glucose and Lipid Profiles

Overview
Journal Heart Vessels
Date 2012 Mar 27
PMID 22447467
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Previous studies have shown highly effective lowering of blood pressure with thiazide diuretics in combination with angiotensin receptor blockers. However, thiazide diuretics may cause the development of diabetes and abnormal lipid metabolism. Little is known as to whether dysmetabolic potential of thiazide diuretics could be neutralized when adding angiotensin receptor blockers. This study consisted of 26 patients with essential hypertension. Patients were randomized to 24 weeks of treatment with either candesartan, 12 mg monotherapy (n = 13, group A), or hydrochlorothiazide (HCTZ), 6.25 mg in combination with candesartan, 8 mg (n = 13, group B). Before and after treatment, we assessed glucose and lipid profiles including adiponectin, resistin, and active glucagon-like peptide-1 (GLP-1) levels. At baseline, there were no differences in age, body mass index, systolic blood pressure (SBP), and diastolic blood pressure (DBP), as well as plasma levels of hemoglobin A1c, insulin, low-density lipoprotein cholesterol, triglycerides, adiponectin, resistin, and active GLP-1 between the two groups. There were significant reductions in SBP (from 152 ± 10 mmHg at baseline to 134 ± 12 mmHg after treatment) and DBP (from 84 ± 5 mmHg at baseline to 71 ± 8 mmHg after treatment) in group A. There were also significant reductions in SBP (from 148 ± 10 at baseline to 128 ± 7 mmHg after treatment) and DBP (from 90 ± 9 at baseline to 74 ± 12 mmHg after treatment) in group B. There were no differences in reduction of SBP or DBP after 24 weeks of treatment between the two groups. There were no changes of the glucose and lipid profiles, including adiponectin, resistin, insulin, and active GLP-1 levels after 24 weeks of treatment in both groups. A low dose of HCTZ in combination with candesartan reduces blood pressure effectively without adverse effects on the glucose and lipid profiles. Therefore, the combination of thiazide diuretics and angiotensin receptor blockers could assist patients in achieving long-term control of blood pressure with good tolerability.

Citing Articles

Association of Thiazide-Type Diuretics With Glycemic Changes in Hypertensive Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.

Zhang X, Zhao Q J Clin Hypertens (Greenwich). 2015; 18(4):342-51.

PMID: 26395424 PMC: 8031670. DOI: 10.1111/jch.12679.


The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases.

Abraham H, White C, White W Drug Saf. 2014; 38(1):33-54.

PMID: 25416320 PMC: 4303500. DOI: 10.1007/s40264-014-0239-7.


Impact of chronic diuretic treatment on glucose homeostasis.

Buscemi S, Nicolucci A, Lucisano G, Galvano F, Grosso G, Massenti F Diabetol Metab Syndr. 2013; 5(1):80.

PMID: 24330854 PMC: 3880098. DOI: 10.1186/1758-5996-5-80.


Olmesartan reduces inflammatory biomarkers in patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the OLIVUS trial.

Miyoshi T, Hirohata A, Usui S, Yamamoto K, Murakami T, Komatsubara I Heart Vessels. 2013; 29(2):178-85.

PMID: 23563752 DOI: 10.1007/s00380-013-0343-0.

References
1.
Ram C . Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies. J Clin Hypertens (Greenwich). 2004; 6(10):569-77. PMC: 8109493. DOI: 10.1111/j.1524-6175.2004.02632.x. View

2.
Legakis I, Tzioras C, Phenekos C . Decreased glucagon-like peptide 1 fasting levels in type 2 diabetes. Diabetes Care. 2002; 26(1):252. DOI: 10.2337/diacare.26.1.252. View

3.
Julius S, Kjeldsen S, Weber M, Brunner H, Ekman S, Hansson L . Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004; 363(9426):2022-31. DOI: 10.1016/S0140-6736(04)16451-9. View

4.
Reinehr T, de Sousa G, Roth C . Fasting glucagon-like peptide-1 and its relation to insulin in obese children before and after weight loss. J Pediatr Gastroenterol Nutr. 2007; 44(5):608-12. DOI: 10.1097/MPG.0b013e3180406a24. View

5.
Hirose H, Kawabe H, Saito I . Effects of losartan/hydrochlorothiazide treatment, after change from ARB at usual dosage, on blood pressure and various metabolic parameters including high-molecular weight adiponectin in Japanese male hypertensive subjects. Clin Exp Hypertens. 2010; 33(1):41-6. DOI: 10.3109/10641963.2010.503301. View